Advertisement
Singapore markets close in 3 hours 29 minutes
  • Straits Times Index

    3,175.91
    +3.98 (+0.13%)
     
  • Nikkei

    39,917.65
    +177.25 (+0.45%)
     
  • Hang Seng

    16,559.69
    -177.41 (-1.06%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Bitcoin USD

    64,773.04
    -3,975.52 (-5.78%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.63 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Gold

    2,161.90
    -2.40 (-0.11%)
     
  • Crude Oil

    82.58
    -0.14 (-0.17%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,550.00
    -3.64 (-0.23%)
     
  • Jakarta Composite Index

    7,344.13
    +41.68 (+0.57%)
     
  • PSE Index

    6,897.97
    +44.68 (+0.65%)
     

Novartis sticks to $200 million FY Entresto forecast after recommendation

ZURICH (Reuters) - Novartis on Monday stuck to its full-year forecast of $200 million (138 million pounds) in revenue from its new heart failure medicine Entresto "as of right now", even as analysts raised their estimates following an endorsement in global medical guidelines.

"We're confident in the forecast we've laid out in the first-quarter call," Chief Medical Officer Vas Narasimhan said in an interview. "As of right now, there's no changes to the outlook but we are also extremely confident in the long-term outlook for this product."

The company has forecast peak annual sales eventually topping $5 billion.

Introduced last year, Entresto got off to a sluggish start, with only $17 million first-quarter sales. On Saturday, however, U.S. and European heart experts gave the highest "Class 1" recommendation to the medicine, buoying optimism sales in both regions will accelerate.

Analysts at Leerink on Monday boosted their forecasts for the drug in 2016 to $250 million.

(Reporting by John Miller, editing by David Evans)